Centene is expected to report Q3 2026 revenue of $47.11 billion and adjusted earnings of $0.07 per share, with its current price of $70.20 sitting just below the average analyst target of $71.78.
Investors are primarily focused on the Medicaid Health Benefit Ratio (HBR) as a signal of margin stabilization following the completion of pandemic-era redeterminations.
While Q3 is seasonally anticipated as an earnings trough due to Medicare Part D dynamics, the recent raising of the full-year EPS guidance floor to over $4.80 has shifted attention to the 2027 recovery path. Significant debt reduction and operational improvements in behavioral health are expected to further support this long-term growth narrative.